Get the Stockscreener App
3.14
6.27%
-0.21
Nuvation Bio Inc stock is traded at $3.14, with a volume of 7.93M.
It is down -6.27% in the last 24 hours and up +35.34% over the past month.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
See More
Previous Close:
$3.35
Open:
$3.34
24h Volume:
7.93M
Relative Volume:
1.21
Market Cap:
$1.07B
Revenue:
-
Net Income/Loss:
$-75.80M
P/E Ratio:
-8.9714
EPS:
-0.35
Net Cash Flow:
$-68.07M
1W Performance:
-19.49%
1M Performance:
+35.34%
6M Performance:
+40.18%
1Y Performance:
+2.61%
1-Day Range:
$3.08
$3.35
1-Week Range:
$3.08
$3.83
52-Week Range:
$1.54
$4.0899
Nuvation Bio Inc Stock (NUVB) Company Profile
Name
Nuvation Bio Inc
Sector
Industry
Phone
(415) 754-3517
Address
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
Compare NUVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
3.14 | 1.14B | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Mar-27-24 | Upgrade | Jefferies | Hold → Buy |
| Mar-26-24 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-06-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-02-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Aug-02-22 | Downgrade | BTIG Research | Buy → Neutral |
| May-04-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-06-21 | Initiated | RBC Capital Mkts | Outperform |
| Mar-08-21 | Initiated | BMO Capital Markets | Outperform |
| Mar-08-21 | Initiated | BTIG Research | Buy |
| Mar-08-21 | Initiated | Cowen | Outperform |
| Mar-08-21 | Initiated | Jefferies | Buy |
| Mar-08-21 | Initiated | Wedbush | Outperform |
View All
Nuvation Bio Inc Stock (NUVB) Latest News
Exome Asset Management LLC Acquires Shares of 96,311 Nuvation Bio Inc. $NUVB - MarketBeat
Nuvation Bio (NYSE:NUVB) Trading Down 15.5%What's Next? - MarketBeat
American Century Companies Inc. Buys 75,362 Shares of Nuvation Bio Inc. $NUVB - MarketBeat
Nuvation Bio (NYSE:NUVB) Earns Outperform Rating from Wedbush - MarketBeat
Nuvation Bio’s Phase 3 Study on Taletrectinib: A Potential Game-Changer for NSCLC Treatment - MSN
Nuvation Bio (NYSE:NUVB) Trading 4.9% HigherTime to Buy? - MarketBeat
AWM Investment Company Inc. Purchases New Holdings in Nuvation Bio Inc. $NUVB - MarketBeat
Nuvation Bio Inc. Stock Lags Behind Sector BenchmarksWeekly Trend Report & Free Safe Entry Trade Signal Reports - beatles.ru
Nuvation Bio Stock: Time to Buy or Sell? - timothysykes.com
These 3 Biopharma Underdogs Could Show Some Bite Soon - TheStreet Pro
Nuvation Bio Says Potential Non-Small Cell Lung Cancer Drug Shows 'Impressive' Progression-Free Survival - MarketScreener
Does Nuvation Bio Inc. stock benefit from AI growthQuarterly Earnings Summary & Target Return Focused Picks - beatles.ru
Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Game-Changer for Glioma Treatment - TipRanks
Nuvation Bio Shines with New Price Target and Bullish Signals - timothysykes.com
Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer - Business Wire
MPM Bioimpact LLC Acquires 488,065 Shares of Nuvation Bio Inc. $NUVB - MarketBeat
Can volume confirm reversal in Nuvation Bio Inc.July 2025 Decliners & Consistent Return Strategy Ideas - Newser
Analyzing drawdowns of Nuvation Bio Inc. with statistical tools2025 Momentum Check & Daily Stock Trend Reports - Newser
Nuvation Bio Stock Gains Momentum Amid Analyst Upgrades and Strategic Engagement - StocksToTrade
Nuvation Bio Stock Shows Potential with Strategic Developments - timothysykes.com
Nuveen LLC Invests $799,000 in Nuvation Bio Inc. $NUVB - MarketBeat
Nuvation Bio Surges on Analyst Upgrades and Bullish Momentum - StocksToTrade
What does recent volatility data suggest for Nuvation Bio Inc.Buy Signal & Safe Capital Growth Plans - Newser
Nuvation Bio stock climbs 16.67% on FDA approval of lung cancer drug - Mugglehead Magazine
Is Nuvation Bio Inc. forming a breakout patternQuarterly Market Summary & Weekly High Return Stock Forecasts - خودرو بانک
Is Nuvation Bio Inc. being accumulated by smart money - خودرو بانک
How sensitive is Nuvation Bio Inc. to inflationTrade Performance Summary & Weekly Breakout Opportunity Watchlist - خودرو بانک
Nuvation Bio stock reaches 52-week high at 3.46 USD By Investing.com - Investing.com Australia
Top 2 Health Care Stocks That May Plunge This Month - Benzinga
Using Bollinger Bands to evaluate Nuvation Bio Inc.2025 Bull vs Bear & Real-Time Volume Analysis - Newser
Heatmap analysis for Nuvation Bio Inc. and competitorsTrade Ideas & Risk Controlled Swing Trade Alerts - Newser
Will earnings trigger a reversal in Nuvation Bio Inc.2025 Risk Factors & Weekly Watchlist for Consistent Profits - Newser
What recovery options are there for Nuvation Bio Inc.July 2025 Summary & Daily Technical Stock Forecast Reports - Newser
What’s next for Nuvation Bio Inc. stock priceMarket Trend Report & Smart Swing Trading Alerts - Newser
Real time scanner hits for Nuvation Bio Inc. explainedJuly 2025 Snapshot & Low Drawdown Momentum Trade Ideas - Newser
What indicators show strength in Nuvation Bio Inc.2025 Macro Impact & Free Daily Entry Point Trade Alerts - Newser
How to manage a losing position in Nuvation Bio Inc.Trade Ideas & Safe Capital Preservation Plans - Newser
Will a bounce in Nuvation Bio Inc. offer an exitJuly 2025 Analyst Calls & Free Daily Entry Point Trade Alerts - Newser
Exit strategy if you’re trapped in Nuvation Bio Inc.July 2025 Snapshot & Free High Accuracy Swing Entry Alerts - Newser
Nuvation Bio stock reaches 52-week high at 3.46 USD - Investing.com
Regression analysis insights on Nuvation Bio Inc. performanceJuly 2025 Update & Safe Entry Point Alerts - Newser
Published on: 2025-09-04 02:16:48 - Newser
What are Nuvation Bio Inc.’s earnings expectationsPortfolio Gains Summary & Weekly High Return Forecasts - خودرو بانک
Nuvation Bio (NUVB) Surges 6.78% to 2025 High on Pipeline Momentum, Analyst Optimism - AInvest
Is Nuvation Bio Inc. stock bottoming outPortfolio Return Report & Smart Allocation Stock Tips - Newser
Can Nuvation Bio Inc. rally from current levelsEarnings Growth Report & Free Expert Verified Stock Movement Alerts - Newser
Momentum divergence signals in Nuvation Bio Inc. chart2025 EndofYear Setup & Safe Entry Zone Tips - Newser
Nuvation Bio Inc. stock outlook for YEARJuly 2025 Drop Watch & Weekly Setup with High ROI Potential - Newser
Advanced analytics toolkit walkthrough for Nuvation Bio Inc.Weekly Market Report & Free High Return Stock Watch Alerts - Newser
Will Nuvation Bio Inc. rebound enough to break evenPortfolio Risk Report & Weekly Chart Analysis and Guides - Newser
Is Nuvation Bio Inc. stock poised for growthMarket Weekly Review & Fast Exit/Entry Strategy Plans - Newser
Nuvation Bio Inc Stock (NUVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):